Wrong evidence transfer
Growth-hormone release from a small molecule does not make it a peptide or give it the evidence profile of a peptide hormone.
Classification guide · O-016
Products sold beside peptides that are not peptides
Catalogue placement is not chemical classification. Small molecules, SARMs, hormones and peptides require different evidence, tests and legal analysis.
Products such as ibutamoren, enobosarm and cardarine may appear beside peptides, but they are not peptides. Their chemical class, mechanism, analytical methods, regulatory position and anti-doping treatment must be checked on their own terms.
The practical mistake is not merely a naming error. A peptide-focused purity method may be unsuitable for a small molecule; medicine and sport rules may classify substances by mechanism; and evidence for one category cannot validate another.
Classification table
Common examples and what they actually are
| Name | Chemical or pharmacological class | Why the distinction matters |
|---|---|---|
| Ibutamoren / MK-677 | Orally active small-molecule ghrelin receptor agonist | Not a peptide secretagogue; evidence, impurities and sport analysis follow the exact molecule and mechanism |
| Enobosarm / ostarine / MK-2866 | Nonsteroidal selective androgen receptor modulator | SARM risks and anti-doping rules apply; peptide tests do not identify it |
| Cardarine / GW501516 | Small-molecule PPAR-delta agonist | It is not a SARM or peptide; its safety history and prohibited status are molecule-specific |
| 5-amino-1MQ | Small-molecule NNMT inhibitor used in preclinical research | Mechanistic research does not establish a consumer medicine or peptide claim |
| Peptide hormone or analogue | A chain of amino acids with sequence-specific identity | Sequence, related peptides, counterions, aggregation and degradation may require peptide-suitable methods |
Decision consequences
The wrong category creates four wrong answers
Wrong laboratory method
Chromatography can separate many substances, but standards, detection, extraction and impurity targets must match the analyte.
Wrong regulatory shortcut
UK medicine status depends on the product, presentation and function. The seller category does not decide it.
Wrong sport conclusion
The WADA List names some substances and also uses classes and mechanisms. Check the exact current entry.
Testing logic
Why the wrong molecule needs a different test
A result is meaningful only when the method is suitable for the question.
Mass spectrometry and chromatography can contribute to identity and quantity, but “HPLC tested” is not a complete method description. The laboratory needs an appropriate reference standard, validated separation, detection, calibration and acceptance criteria for the exact substance.
A method built to assess a peptide sequence and peptide-related impurities may miss a small-molecule substitution. Conversely, a small-molecule assay may not resolve peptide truncations, oxidation products or aggregates. Sterility and endotoxin remain separate from chemical identity for any injectable product.
Catalogue literacy
Labels that do not settle the classification
“Research peptide”
A sales category. It does not prove peptide chemistry, legal research supply or product quality.
“Secretagogue”
A functional description. Peptides and small molecules can both stimulate hormone release through different receptors.
“SARM”
A pharmacological class, not a synonym for every performance product. Cardarine is often grouped with SARMs but acts through PPAR-delta.
“99% pure”
A method-dependent number. It does not by itself prove identity, amount, sterility, endotoxin control or clinical safety.
Decision boundary
What remains unknown
- Whether the seller has named the chemical entity correctly.
- Whether the tested method can distinguish the claimed molecule from substitutions and related impurities.
- Whether quantity, stereochemistry, salt form and degradation products were measured.
- Whether an injectable product is sterile and acceptably controlled for endotoxin.
- How the exact product is classified under current UK law.
- Whether the exact substance or mechanism appears on the current WADA Prohibited List.
Practical workflow
Classify the molecule before reading the certificate
Start with an unambiguous chemical name, structure or amino-acid sequence and list the aliases that sellers use. Then verify whether the product claims a free base, salt, counterion, stereoisomer, fragment or modified analogue. These details determine which reference standard and impurity targets a laboratory should use.
Next, match the evidence to that exact entity and route. Only then check UK medicine status and the current WADA List. This order prevents a familiar catalogue label from deciding the chemistry, evidence and rules before the object has been identified.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| FDA: warning about SARMs in bodybuilding products | SARMs sold in bodybuilding products are unapproved drugs associated with serious safety concerns. | It does not establish the content of a particular UK product. | |
| PubChem: Ibutamoren | Chemical identity and small-molecule classification for ibutamoren. | A chemical database entry does not establish medicine authorisation or product purity. | |
| PubChem: Enobosarm | Chemical identity for the nonsteroidal SARM enobosarm. | It does not verify an ostarine product. | |
| PubChem: Cardarine | Chemical identity for GW501516 as a small molecule. | It does not establish safety or a seller product. | |
| WADA: 2026 Prohibited List | The current anti-doping categories and named examples for 2026. | The List does not prove product identity or determine ordinary UK medicine law. |
Continue the investigation
Read the connected evidence
- why the wrong molecule needs a different testMatch each claim to a fit-for-purpose analytical method.
- experimental peptide evidence profilesReturn to the molecule and alias index.
- UK peptide regulationApply current medicine and product rules to the exact presentation.
- testing and certificate basicsRead reports without turning one method into a global quality grade.
Quick answers
Frequently asked questions
Is MK-677 a peptide?
No. Ibutamoren, also called MK-677, is a small-molecule ghrelin receptor agonist.
Is ostarine a peptide?
No. Ostarine, also called enobosarm or MK-2866, is a nonsteroidal selective androgen receptor modulator.
Is cardarine a SARM?
No. Cardarine, or GW501516, is a PPAR-delta agonist. It is often sold beside SARMs but belongs to a different pharmacological class.
Why does chemical class matter for testing?
Reference standards, extraction, separation, detection and impurity targets must fit the exact analyte. A generic purity claim cannot substitute for that detail.
Does “research peptide” prove a product is a peptide?
No. It is catalogue language, not structural evidence or a legal classification.
Can the WADA List settle whether a product is legal in the UK?
No. Anti-doping rules and UK medicines law answer different questions. Check both independently.
Editorial experience
From our work: how we checked this page
For topical-map item O-016, Products sold beside peptides that are not peptides was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 6 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.